Clinical trials: Hair Problems
Alopecia Areata
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AA2 (NCT04797650)
- Testing
- CTP-543
- Where
- 63 sites in United States, Canada and 5 more
- Volunteers
- 517 people
- Sponsor
- Concert Pharmaceuticals
Scarring Alopecia, Androgenetic Alopecia
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.
- Trial name
- NCT05460611
- Testing
- Sciton HALO 1470nm Non-ablative laser
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Alopecia Areata
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
- Trial name
- NCT05556265
- Testing
- Deucravacitinib
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Bristol-Myers Squibb
Androgenetic Alopecia
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic…
- Trial name
- NCT03742518
- Testing
- Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 675 people
- Sponsor
- Biosplice Therapeutics, Inc.
Hair Loss
TCI999 in the Efficacy Verification Program of Hair and Body Health Care
To assess TCI999 on hair and body health care
- Trial name
- NCT05077553
- Testing
- TCI999 probiotic sachet
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Keloid, Alopecia Areata
Pain Outcomes Following Intralesional Corticosteroid Injections
Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics.
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar
- Trial name
- NCT03630198
- Testing
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Alopecia Areata
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03811912
- Testing
- CTP-543
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Concert Pharmaceuticals
Alopecia Areata
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AA1 (NCT04518995)
- Testing
- CTP-543
- Where
- 72 sites in United States, Canada and 3 more
- Volunteers
- 706 people
- Sponsor
- Concert Pharmaceuticals
Alopecia, Lichen Planus
Study of the Characteristics of Pruritus in Patients With Frontal Fibrosing Alopecia or Lichen Planus Pilaris
The prevalence of pruritus has been studied in frontal fibrosis alopecia (FFA) and lichen planus pilaris (LPP), but there are no studies evaluating the characteristics of pruritus, the correlation between pruritus and disease…
- Trial name
- PRURIT-ALOPECI (NCT05761158)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 21 people
- Sponsor
- University Hospital, Brest
Breast Cancer Female, Alopecia
Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy
Chemotherapy (CT) is a frequent and well established treatment in women with breast and gynecological tumors. Alopecia is one of the most common side effects of CT seriously impairing patient quality of life and body image.
- Trial name
- NCT04117815
- Testing
- Paxman Scalp Cooling System, Alopecia Assessments
- Where
- Austria
- Volunteers
- 128 people
- Sponsor
- Medical University Innsbruck
Androgenetic Alopecia
A Study on the Efficacy and Safety of Microneedling for Male Androgenetic Alopecia
Androgenetic alopecia (AGA) is the most prevalent hair-loss disorder in clinical practice. With a high incidence rate, it not only severely impairs patients' appearance and quality of life, but may also trigger varying degrees of…
- Trial name
- NCT07758400
- Testing
- Minoxidil 5 %, Microneedling
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Cheng Zhou
Alopecia Areata
Role of Minoxidil in Alopecia Areata Transepidermal Drug Delivery of Minoxidil Via Either Fractional Carbon Dioxide Laser or Microneedling Versus Its Topical Nanoparticles Preparation for Treatment of Alopecia Areata
Compare the clinical efficacy, and safety of transepidermal drug delivery of fractional CO2 laser versus microneedling followed by minoxidil 5% application for the treatment of alopecia areata.
- Trial name
- NCT05587257
- Testing
- Fractional CO2 laser, Derma pen, Niosome minoxidil
- Volunteers
- 60 people
- Sponsor
- Assiut University
Hypertrichosis
Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes
Objective: To determine if Lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes.
- Trial name
- NCT00773136
- Testing
- Bimatoprost Suspension
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Miami
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Hypotrichosis
Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo
The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows.
- Trial name
- NCT01387906
- Testing
- topical bimatoprost
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kenneth Beer
Androgenetic Alopecia
Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia
Androgenetic alopecia is a common condition affects both genders. Patients of androgenetic alopecia following inclusion criteria will be enrolled after ethical approval and informed consent.
- Trial name
- NCT06239207
- Testing
- Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%), Platelet Rich Plasma
- Where
- Pakistan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Services Hospital, Lahore
Alopecia Areata (AA), Alopecia Totalis (AT)
Tofacitnib for the Treatment of Alopecia Areata and Variants
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
- Conditions
- Alopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)
- Trial name
- NCT02197455
- Testing
- Tofacitinib Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Hair Thinning
Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Thinning Hair
The Viviscal Extra-Strength formulation is an oral food/dietary supplement specifically designed to promote hair growth for women suffering from temporary thinning hair.
- Trial name
- NCT02297360
- Testing
- Viviscal Extra-Strength Supplement
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ablon Skin Institute Research Center
Atopic Dermatitis, Psoriasis
Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions
The purpose of this investigation is to study the effectiveness of longer wavelength UVA1 (340-400nm) or shorter wavelength ultraviolet B [UVB] (290-320nm) irradiation in the treatment of inflammatory skin conditions (such as…
- Conditions
- Atopic Dermatitis, Psoriasis, Alopecia, Mycosis Fungoides
- Trial name
- NCT00129415
- Testing
- UVA1 Irradiation, UVB Irradiation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Michigan
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP1 (NCT05910450)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 24 sites in United States, Georgia
- Volunteers
- 703 people
- Sponsor
- Cassiopea SpA